2023
Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells
Xu S, Ren J, Lewis J, Carlson K, Girardi M. Proteasome Inhibitors Interact Synergistically with BCL2, Histone Deacetylase, BET, and Jak Inhibitors against Cutaneous T-Cell Lymphoma Cells. Journal Of Investigative Dermatology 2023, 143: 1322-1325.e3. PMID: 36642402, DOI: 10.1016/j.jid.2022.12.017.Peer-Reviewed Original Research
2022
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Zeleke T, Pan Q, Chiuzan C, Onishi M, Li Y, Tan H, Alvarez M, Honan E, Yang M, Chia P, Mukhopadhyay P, Kelly S, Wu R, Fenn K, Trivedi M, Accordino M, Crew K, Hershman D, Maurer M, Jones S, High A, Peng J, Califano A, Kalinsky K, Yu J, Silva J. Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature Cancer 2022, 4: 257-275. PMID: 36585452, PMCID: PMC9992270, DOI: 10.1038/s43018-022-00489-5.Peer-Reviewed Original ResearchConceptsBreast cancerDose-escalation clinical trialHDAC6 inhibitor ricolinostatMetastatic breast cancerPan-HDAC inhibitorsHistone deacetylaseHuman breast cancerIndividual histone deacetylaseSensitive cancer cellsNab-paclitaxelClinical responseMetastatic BCPredictive biomarkersClinical trialsClinical activityPreclinical studiesTumor typesHDAC6 activityCancer cellsHDAC6iAnticancer strategyPatientsRicolinostatCancerMultiple cohortsPlant-specific HDT family histone deacetylases are nucleoplasmins
Bobde R, Kumar A, Vasudevan D. Plant-specific HDT family histone deacetylases are nucleoplasmins. The Plant Cell 2022, 34: 4760-4777. PMID: 36069647, PMCID: PMC9709999, DOI: 10.1093/plcell/koac275.Peer-Reviewed Original ResearchConceptsN-terminal domainHistone chaperonesH2A/H2B dimersHistones H3/H4H3/H4Nucleosome dynamicsH2B dimersSequence similarityHistone acetyltransferaseEnigmatic familyHistone acetylationFunctional characterizationNucleoplasminGene expressionHistone deacetylasesC-terminalHistone deacetylaseUrea conditionsHistone oligomersSolution structureChaperonesDifferent familiesArabidopsis
2021
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome
Scotto L, Kinahan C, Douglass E, Deng C, Safari M, Casadei B, Marchi E, Lue JK, Montanari F, Falchi L, Qiao C, Renu N, Bates SE, Califano A, O'Connor OA. Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling PathwaysTargeting Peripheral T-Cell Lymphoma Epigenome. Molecular Cancer Therapeutics 2021, 20: 1422-1430. PMID: 34108263, PMCID: PMC8941846, DOI: 10.1158/1535-7163.mct-20-0377.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, NeoplasmAntimetabolites, AntineoplasticApoptosisAzacitidineBiomarkers, TumorCell ProliferationDNA (Cytosine-5-)-Methyltransferase 1DNA MethylationEpigenesis, GeneticEpigenomeGene Expression ProfilingGene Expression Regulation, NeoplasticHistone Deacetylase InhibitorsHumansImmunityLymphoma, T-CellMaleTestisTumor Cells, CulturedConceptsEpigenetic geneHistone deacetylaseSuppression of genesHDAC inhibitorsDNA methyltransferase inhibitorTranscriptional inductionDNA methylationMaster regulatorDNMT inhibitorsEpigenetic diseasePeripheral T-cell lymphomaGene expressionMethyltransferase inhibitorMechanistic basisCell deathGenesCancer-testis antigensTestis antigensEpigenomeMutationsCholesterol metabolismInhibitorsInductionMatrisomeTh1-like phenotypeTargeting smooth muscle cell phenotypic switching in vascular disease
Chakraborty R, Chatterjee P, Dave JM, Ostriker AC, Greif DM, Rzucidlo EM, Martin KA. Targeting smooth muscle cell phenotypic switching in vascular disease. JVS Vascular Science 2021, 2: 79-94. PMID: 34617061, PMCID: PMC8489222, DOI: 10.1016/j.jvssci.2021.04.001.Peer-Reviewed Original ResearchSingle-cell transcriptomicsVascular smooth muscle cellsVSMC phenotypic modulationPhenotypic plasticityCell transcriptomicsPhenotypic modulationMature vascular smooth muscle cellsSmooth muscle cell phenotypicLineage tracing methodStriking diversityFundamental new insightsMolecular mechanismsFate mappingRemarkable plasticityBromodomain inhibitorsHistone deacetylasePhenotypic switchingPharmacologic inhibitorsGenetic targetingVSMC phenotypicDruggable pathwaysSmooth muscle cellsOligoclonal lesionsTranscriptomicsRecent discovery
2020
Histone sumoylation promotes Set3 histone-deacetylase complex-mediated transcriptional regulation
Ryu HY, Zhao D, Li J, Su D, Hochstrasser M. Histone sumoylation promotes Set3 histone-deacetylase complex-mediated transcriptional regulation. Nucleic Acids Research 2020, 48: gkaa1093-. PMID: 33231641, PMCID: PMC7708062, DOI: 10.1093/nar/gkaa1093.Peer-Reviewed Original ResearchConceptsHistone deacetylase complexSet3 histone deacetylase complexHistone sumoylationTrans-tail regulationGenome-wide analysisSUMO-interacting motifSUMO conjugation pathwayAltered gene expression profilesDeacetylation of histonesGene expression profilesSet3 complexH2B ubiquitylationDeacetylase complexSpurious transcriptionRNA genesTranscriptional regulationActive genesTranscriptional fidelityTranscription initiationSUMOylationMRNA genesExpression profilesCrosstalk pathwaysHistone deacetylaseGenes
2018
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants
Kalu NN, Mazumdar T, Peng S, Tong P, Shen L, Wang J, Banerjee U, Myers JN, Pickering CR, Brunell D, Stephan CC, Johnson FM. Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants. Cancer Letters 2018, 431: 64-72. PMID: 29807113, DOI: 10.1016/j.canlet.2018.05.029.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisArea Under CurveAurora Kinase ABenzamidesBiomarkersCarcinoma, Squamous CellCell CycleCell LineCell ProliferationDNA-Binding ProteinsDrug Evaluation, PreclinicalFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiceMutationNeoplasm ProteinsNeoplasm TransplantationPapillomaviridaePapillomavirus InfectionsPharmacogeneticsPyrazolesUterine Cervical NeoplasmsConceptsAurora kinase inhibitorsDrug sensitivityWild-type cellsPolo-like kinasesInhibitor-induced apoptosisHigh-throughput drug screensNeck squamous cell carcinomaKinase inhibitorsHPV-negative cell linesSquamous cell carcinomaEffective drug classAurora kinase inhibitionG2-M arrestAurora kinasesHistone deacetylaseAurora inhibitorsCervical cancerTumor sizeCell carcinomaHuman papillomavirusCancer DatabaseDrug classesPharmacogenomic profilingXenograft modelM arrest
2017
BET inhibitors: a novel epigenetic approach
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Annals Of Oncology 2017, 28: 1776-1787. PMID: 28838216, DOI: 10.1093/annonc/mdx157.Peer-Reviewed Original ResearchConceptsBET inhibitorsHDAC inhibitorsEpigenetic agentsExtra-terminal motif (BET) proteinsImmune checkpoint inhibitorsEarly clinical trialsNovel epigenetic approachHistone deacetylaseZeste homolog 2BET proteinsMonotherapy activityCheckpoint inhibitorsTargeted agentsPreclinical dataClinical trialsDrug classesDrug combinationsSingle agentSolid tumorsPreclinical researchTumor cellsHomolog 2Lysine-specific demethylase 1Anticancer therapyInhibitors
2015
A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, W. A, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2015, 21: 1566-1573. PMID: 25573383, PMCID: PMC6607903, DOI: 10.1158/1078-0432.ccr-14-2820.Peer-Reviewed Original ResearchConceptsHuman growth factor receptor 2Peripheral blood mononuclear cellsEpidermal growth factor receptorDose-limiting toxicityAdverse eventsCUDC-101Tumor biopsiesHistone deacetylaseNeck squamous cell cancerNeck squamous cell carcinomaHigh-risk HNSCCGrowth factor receptor 2Squamous cell cancerSquamous cell carcinomaBlood mononuclear cellsExternal beam radiationTreatment of HNSCCRoute of administrationOne-week runFactor receptor 2Concurrent cisplatinGrowth factor receptorRisk patientsCell cancerCell carcinoma
2013
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabDrug DesignDrug Resistance, NeoplasmErbB ReceptorsHead and Neck NeoplasmsHistone Deacetylase InhibitorsHumansMolecular Targeted TherapyPapillomaviridaeProtein Kinase InhibitorsProto-Oncogene Proteins c-metReceptor, ErbB-2Signal TransductionTreatment OutcomeConceptsHPV-negative headNeck cancerHuman papillomavirusEGFR inhibitionSingle-agent cetuximabLow cure rateMonoclonal antibody cetuximabActive therapyCytotoxic chemotherapyDisease survivalCure rateMechanisms of resistanceAntibody cetuximabResponse rateCetuximabEGFRNovel targetReceptor tyrosine kinasesCancerTherapyHistone deacetylaseChemotherapyHabitual exposureModest effectNuclear functions
2004
Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1
Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE. Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Human Molecular Genetics 2004, 13: 2399-2408. PMID: 15333582, DOI: 10.1093/hmg/ddh271.Peer-Reviewed Original ResearchConceptsDNA cross-linking agentsNucleotide excision repairDNA damage-induced mutationsTumor suppressor geneDamage-induced mutationsDrosophila homologGenomic integrityHuman meninMutant fliesBiochemical functionsTranscriptional modulationNuclear proteinsDrosophila modelProtein 50Novel memberExcision repairNull allelesMolecular mechanismsCancer genesHistone deacetylaseSuppressor geneHomozygous inactivationMnn1Normal fliesGenes
2002
Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene
Shao RH, Tian X, Gorgun G, Urbano AG, Foss FM. Arginine butyrate increases the cytotoxicity of DAB389IL-2 in leukemia and lymphoma cells by upregulation of IL-2Rβ gene. Leukemia Research 2002, 26: 1077-1083. PMID: 12443879, DOI: 10.1016/s0145-2126(02)00059-0.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArginineButyratesCell SurvivalCyclic AMPDiphtheria ToxinDose-Response Relationship, DrugDrug SynergismHumansInterleukin-2Interleukin-2 Receptor beta SubunitLeukemiaLymphomaReceptors, InterleukinReceptors, Interleukin-2Recombinant Fusion ProteinsResponse ElementsSecond Messenger SystemsUp-RegulationConceptsCutaneous T-cell lymphomaIL-2R expressionNon-Hodgkin lymphomaArginine butyrateIL-2RLow affinity IL-2RHistone deacetylaseDirect growth-inhibitory effectB-cell non-Hodgkin lymphomaHigh-affinity IL-2 receptorLeukemia cellsCAMP response elementT-cell lymphomaIL-2 receptorNative diphtheria toxinGrowth inhibitory effectsClinical trialsP75 subunitAchievable concentrationsResponse rateVitro dataDAB389IL-2Interleukin-2 geneTumor cellsLymphoma cells
1999
Cloning and Characterization of the Murine Histone Deacetylase (HDAC3)
Mahlknecht U, Hoelzer D, Bucala R, Verdin E. Cloning and Characterization of the Murine Histone Deacetylase (HDAC3). Biochemical And Biophysical Research Communications 1999, 263: 482-490. PMID: 10491319, DOI: 10.1006/bbrc.1999.1389.Peer-Reviewed Original ResearchConceptsHistone deacetylasesCore histone proteinsHuman chromosome 5q31Potential tumor suppressor geneHistone acetylation modifiersMalignant myeloid diseasesTumor suppressor geneHistone proteinsTranscriptional complexHistone acetylationDevelopment of cancerHistone deacetylaseSuppressor geneHDAC3Chromosome 5q31Cellular proliferationEnzymatic activityAcetylationMyeloid diseasesImportant insightsOrthologsHistonesCloningDeacetylasesGenes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply